What is prostate cancer?

Prostate cancer is the most common cancer among men in the United States. In 2023, 288 300 cases of prostate cancer are expected to be diagnosed in the country, resulting in 34 700 deaths. Early detection is critical to improve treatment outcomes, reduce mortality and make more efficient use of healthcare resources.

When prostate cancer is suspected, doctors have for many years carried out tests such as the PSA test. A blood test that is one of the first steps in suspicion. Since A3P Biomedical's product Stockholm3 was released on the market, it has become a worthy alternative that can detect aggressive prostate cancer at an early stage. 

 

The collaboration between A3P Biomedical and BioAgilytix

A3P Biomedical and BioAgilytix are collaborating to bring the Stockholm3 test to the U.S. market, with the goal of significantly improving the diagnosis and early detection of prostate cancer. Stockholm3 offers a new opportunity for early detection of the disease, especially for those at risk.

David Rosén, CEO of A3P Biomedical, says the collaboration with BioAgilytix on Stockholm3 is based on a shared commitment to innovation. The aim is to launch Stockholm3 as an LDT for early identification of men at high risk of prostate cancer while reducing unnecessary medical interventions. He emphasizes that the US market, one of the largest globally, would benefit from advanced diagnostics that improve men's health and quality of life.

Linda Robbie, PhD, COO of BioAgilytix, highlights that A3P Biomedical's focus on precision medicine and patient-centered diagnostics complements BioAgilytix's commitment to developing biologics that can transform and save lives. Together, they aim to create a new standard of care by introducing innovative solutions that address previously unmet medical needs.

Recently, the Stockholm3 test was mentioned as a biomarker in the updated American Urological Association (AUA) 2023 guidelines for early detection of prostate cancer. According to the AUA guidelines, based on a study (Grönberg et al. 2015, Lancet Oncology), the Stockholm3 exhibits higher predictive accuracy than the PSA test alone and reduces the need for unnecessary biopsies. 

The guidelines also suggest the use of complementary biomarkers such as Stockholm3 for men with elevated PSA levels or after a negative biopsy where the decision on further biopsy would be affected.

 

The parties involved

About BioAgilytix

BioAgilytix is a leading global provider of bioanalytical services, delivering complex projects in the pharmaceutical and biotechnology sectors through all phases of drug development. With accreditations in GLP, GCP, GMP and CLIA, the company offers a range of services including diagnostics, pharmacokinetics (PK), immunogenicity, biomarkers and cell-based assays from its laboratories in the US, Australia and Germany. More information is available at www.bioagilytix.com.

 

About A3P Biomedical

A3P Biomedical aims to improve the quality of life of men by significantly improving the accuracy of prostate cancer diagnosis. Their lead product, Stockholm3, is a blood-based test developed for the early detection of aggressive prostate cancer, developed by researchers at Karolinska Institutet and validated in clinical studies with over 75,000 men. The headquarters are located in Stockholm, Sweden. More information is available at www.a3p.com.

 

About Stockholm3

Stockholm3 is a blood test that combines protein and genetic biomarkers with clinical data to predict the risk of early-stage aggressive prostate cancer. The test has been shown in clinical practice to find 100% more aggressive cases and reduce unnecessary biopsies by 50% compared to traditional PSA tests. 

Stockholm3 has been validated in studies involving over 75,000 men and has been recognized by the European Association of Urology (EAU) with the 'Prostate Cancer Research Award 2022'. Several studies have been published in reputable scientific journals, including an earlier study of 58,000 men in The Lancet Oncology in 2015. With strong scientific support, leading Nordic healthcare providers have started to replace PSA testing with Stockholm3. 

Region Värmland in Sweden has introduced organized prostate cancer testing with Stockholm3 for men aged 50-75, providing a more accurate test while reducing direct costs by 17 to 28%.

 

Sources

For more detailed information regarding Stockholm3's partnership in the US, please visit A3P's press release.